Analytical methods | ||
---|---|---|
Comparative study | #1 | |
Chromatography | LC | |
Ion source | ESI | |
Positive/Negative mode | both | |
Mass analyzer | Q-TOF | |
Identification level | MS/MS |
Sample information | ||
---|---|---|
Comparative study | #1 | |
Country | China | |
Specimen | Serum | |
Marker function | diagnosis | |
Participants(Case) | Cancer type | LCC, ADC, SCC, SCLC |
Stage | I, II, III, IV | |
Number | 39 | |
Gender (M,F) | 21, 23 | |
Mean age (range) (M,F) | – | |
Smoking status | – | |
Participants(Control) | Type | healthy control |
Number | 40 | |
Gender (M,F) | 18, 27 | |
Mean age (range) (M,F) | – | |
Smoking status | – |
Data processing and metabolite identification | |
---|---|
Data processing software | XCMS, CAMERA, metaX |
Database search | KEGG, HMDB |
Statistical analysis | |
---|---|
Differential analysis method | Student’s t-test, PLS-DA, |
Classification method | – |
Survival analysis method | – |
Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
---|---|---|---|---|---|---|---|
12S-HHT | – | – | – | 4.34 | 1.09e-06 | – | 3.84 |
LysoPC 14:0 | – | – | – | 3.68 | 1.73e-07 | – | 3.52 |
beta-Santalyl acetate | – | – | – | 3.37 | 1.24e-06 | – | 3.41 |
LysoPC 16:1 | – | – | – | 3.16 | 5.06e-07 | – | 3.29 |
3-cyclohexyl-1,1-dimethylurea | – | – | – | 3.12 | 1.49e-12 | – | 4.67 |
acetyl-DL-carnitine | – | – | – | 2.96 | 1.34e-05 | – | 2.89 |
docosatrienoic acid | – | – | – | 2.85 | 5.11e-13 | – | 4.06 |
Plasmenyl-PC 16:0; PC(P-14:0/2:0) | – | – | – | 2.84 | 1.01e-07 | – | 3.23 |
LysoPE 18:3 | – | – | – | 2.64 | 7.16e-08 | – | 3.14 |
8Z,14Z-Eicosadienoic acid | – | – | – | 2.42 | 4.10e-03 | – | 1.79 |
5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid, 1,5-lactone | – | – | – | 2.40 | 2.12e-04 | – | 2.67 |
LysoPE 18:2 | – | – | – | 2.32 | 1.76e-07 | – | 2.97 |
desmethylofloxacin | – | – | – | 2.31 | 0.03 | – | 1.30 |
PC 9:0; PC(4:0/5:0) | – | – | – | 2.24 | 9.40e-10 | – | 3.23 |
LysoPA 18:2; LysoPA 18:2 | – | – | – | 2.24 | 7.19e-04 | – | 2.28 |
LysoPC 18:3 | – | – | – | 2.20 | 1.07e-06 | – | 2.75 |
LysoPE 22:6 | – | – | – | 2.18 | 1.31e-05 | – | 2.67 |
LysoPE 20:3 | – | – | – | 2.17 | 1.59e-07 | – | 2.85 |
linoleoylcarnitine | – | – | – | 2.14 | 1.83e-09 | – | 3.08 |
LysoPE 18:1 | – | – | – | 2.11 | 1.33e-07 | – | 2.85 |
dehydrocarpaine I | – | – | – | 2.10 | 7.07e-04 | – | 2.09 |
TG 62:17; TG(18:4/22:6/22:7) | – | – | – | 2.07 | 1.67e-06 | – | 2.65 |
LysoPE 22:5 | – | – | – | 2.06 | 1.87e-03 | – | 1.91 |
TG 66:21; TG(22:7/22:7/22:7) | – | – | – | 2.04 | 2.29e-05 | – | 2.52 |
Plasmenyl-PE 18:0; PE(P-15:0/3:0) | – | – | – | 2.03 | 1.47e-05 | – | 2.45 |
11.alpha.-Hydroxyprogesterone .beta.-D-glucuronide | – | – | – | 2.02 | 1.57e-09 | – | 3.01 |
LysoPE 16:0 | – | – | – | 2.01 | 2.64e-08 | – | 2.86 |
omega.-3 Arachidonic acid methyl ester | – | – | – | 2.01 | 3.37e-05 | – | 2.48 |
acrolein | – | – | – | 1.98 | 7.54e-08 | – | 2.76 |
Trp-Leu | – | – | – | 1.96 | 1.45e-13 | – | 3.32 |
riboflavin | – | – | – | 1.93 | 7.98e-03 | – | 1.65 |
5-hexyltetrahydro-2-furanoctanoic acid | – | – | – | 1.92 | 3.88e-07 | – | 2.71 |
Neurine | – | – | – | 1.90 | 6.78e-09 | – | 2.96 |
Trp-Glu | – | – | – | 1.90 | 3.86e-10 | – | 2.95 |
LysoPC 15:0 | – | – | – | 1.89 | 7.86e-05 | – | 2.20 |
8-HETrE | – | – | – | 1.88 | 5.47e-03 | – | 1.94 |
LysoPE 20:4 | – | – | – | 1.88 | 1.49e-07 | – | 2.65 |
PC(16:0/20:3(5Z,8Z,11Z)) | – | – | – | 1.88 | 4.40e-03 | – | 1.51 |
12R-Hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid | – | – | – | 1.87 | 0.01 | – | 1.96 |
ormosanine | – | – | – | 1.87 | 3.76e-09 | – | 2.71 |
LysoPC 22:5 | – | – | – | 1.85 | 4.36e-05 | – | 2.28 |
L-propionylcarnitine | – | – | – | 1.83 | 5.51e-04 | – | 2.14 |
LysoPC 20:5 | – | – | – | 1.83 | 0.01 | – | 1.94 |
oleoyl-L-carnitine | – | – | – | 1.83 | 5.79e-06 | – | 2.42 |
pyruvic acid | – | – | – | 1.83 | 3.81e-06 | – | 2.39 |
7-hydroxyquetiapine | – | – | – | 1.80 | 1.63e-04 | – | 2.15 |
LysoPC 22:6 | – | – | – | 1.78 | 2.15e-03 | – | 1.90 |
N-lactoyl-leucine | – | – | – | 1.76 | 2.21e-04 | – | 2.13 |
PC(18:3(6Z,9Z,12Z)/16:0) | – | – | – | 1.75 | 0.01 | – | 1.64 |
germbudine | – | – | – | 1.74 | 6.40e-08 | – | 2.50 |
LysoPE 18:0 | – | – | – | 1.72 | 1.17e-04 | – | 2.12 |
ent-16b,19-Kauranediol 19-acetate | – | – | – | 1.72 | 8.22e-03 | – | 1.91 |
LysoPC 20:3 | – | – | – | 1.71 | 9.32e-07 | – | 2.33 |
8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid | – | – | – | 1.70 | 1.11e-05 | – | 2.32 |
Plasmenyl-PC 18:0; PC(P-14:0/4:0) | – | – | – | 1.69 | 4.95e-07 | – | 2.34 |
palmitoylcarnitine | – | – | – | 1.68 | 1.08e-06 | – | 2.33 |
(S)-Reticuline | – | – | – | 1.68 | 1.62e-04 | – | 2.00 |
linoleic acid | – | – | – | 1.68 | 6.17e-03 | – | 1.73 |
1,2-Di-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine | – | – | – | 1.67 | 5.34e-03 | – | 1.54 |
adipoyl-L-carnitine | – | – | – | 1.67 | 2.01e-04 | – | 2.02 |
acylcarnitine 18:3 | – | – | – | 1.66 | 7.05e-06 | – | 2.24 |
methyl .gamma.-linolenate | – | – | – | 1.66 | 3.68e-03 | – | 1.56 |
cocaine | – | – | – | 1.65 | 1.51e-04 | – | 2.36 |
irbesartan | – | – | – | 1.65 | 2.69e-07 | – | 2.34 |
11,14,17-eicosatrienoic acid, (Z,Z,Z)- | – | – | – | 1.64 | 2.09e-05 | – | 2.13 |
LysoPC 17:1 | – | – | – | 1.63 | 2.08e-05 | – | 2.03 |
1-(3-(Trifluoromethyl)phenyl)piperazine | – | – | – | 1.62 | 4.34e-04 | – | 1.81 |
pyroglutamic acid | – | – | – | 1.62 | 1.28e-05 | – | 2.16 |
drofenine | – | – | – | 1.62 | 2.69e-10 | – | 2.53 |
glutamyltryptophan | – | – | – | 1.61 | 3.63e-05 | – | 2.32 |
3-tert-Butyl-4-hydroxyanisole | – | – | – | 1.61 | 1.33e-03 | – | 1.89 |
acylcarnitine 20:3 | – | – | – | 1.60 | 1.80e-04 | – | 2.04 |
6-(3-Dimethylaminopropionyl)forskolin | – | – | – | 1.59 | 3.08e-03 | – | 1.66 |
acylcarnitine 16:1 | – | – | – | 1.59 | 1.80e-03 | – | 1.75 |
LysoPC 20:4 | – | – | – | 1.59 | 5.36e-04 | – | 1.95 |
butaprost (free acid) | – | – | – | 1.59 | 0.03 | – | 1.49 |
4-methylumbelliferone | – | – | – | 1.58 | 1.24e-04 | – | 1.96 |
LysoPC 18:0 | – | – | – | 1.57 | 5.16e-03 | – | 1.57 |
LysoPS 20:4; LysoPS 20:4 | – | – | – | 1.56 | 2.97e-06 | – | 2.25 |
stearamide | – | – | – | 1.56 | 0.03 | – | 1.30 |
LysoPC 16:0 | – | – | – | 1.56 | 7.60e-07 | – | 2.12 |
acylcarnitine 20:2 | – | – | – | 1.55 | 7.58e-06 | – | 2.02 |
chloridazone-methyl-desphenyl | – | – | – | 1.54 | 2.19e-05 | – | 2.03 |
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | – | – | – | 1.54 | 0.04 | – | 1.37 |
2S-Amino-4E-octadecene-1,3S-diol | – | – | – | 1.54 | 3.25e-06 | – | 2.00 |
9-oxoprosta-10,12Z,14E-trienoic acid | – | – | – | 1.53 | 5.55e-03 | – | 1.57 |
2,2,6,7-Tetramethylbicyclo[4.3.0]nona-1(9),4-diene-7,8-diol | – | – | – | 1.52 | 2.91e-03 | – | 1.57 |
methyl dihydrojasmonate | – | – | – | 1.52 | 9.17e-03 | – | 1.33 |
perfluoroundecanoic acid | – | – | – | 1.52 | 0.04 | – | 1.45 |
drostanolone | – | – | – | 1.52 | 2.39e-03 | – | 1.62 |
acylcarnitine 20:1 | – | – | – | 1.50 | 4.80e-03 | – | 1.65 |
3-decen-2-one | – | – | – | 1.50 | 7.72e-03 | – | 1.84 |
Plasmenyl-PC 44:5; PC(P-22:0/22:5) | – | – | – | 1.50 | 2.37e-04 | – | 1.76 |
8-isoprostaglandin E2 | – | – | – | 0.66 | 1.26e-03 | – | 2.02 |
hypoxanthine | – | – | – | 0.66 | 1.19e-03 | – | 3.09 |
2-butyl-4-methylphenol | – | – | – | 0.66 | 7.78e-04 | – | 2.27 |
AcylGlcADG 66:18; AcylGlcADG(22:6/22:6/22:6) | – | – | – | 0.66 | 6.04e-09 | – | 2.36 |
isopropyl tiglate | – | – | – | 0.64 | 2.10e-03 | – | 2.09 |
indoxyl sulfate | – | – | – | 0.63 | 7.97e-03 | – | 2.04 |
paraxanthine | – | – | – | 0.63 | 0.03 | – | 2.26 |
decanoyl-L-Carnitine | – | – | – | 0.63 | 7.68e-04 | – | 2.35 |
octanoylcarnitine | – | – | – | 0.62 | 8.04e-04 | – | 2.17 |
theobromine | – | – | – | 0.60 | 8.60e-03 | – | 3.03 |
inosine | – | – | – | 0.60 | 1.52e-03 | – | 3.25 |
5.alpha.-Androstan-3.beta.-ol-17-one sulfate | – | – | – | 0.59 | 3.80e-03 | – | 2.58 |
acylcarnitine 13:1 | – | – | – | 0.59 | 6.36e-04 | – | 1.98 |
cyclamate | – | – | – | 0.58 | 0.03 | – | 2.07 |
1,2,3-Trihydroxybenzene | – | – | – | 0.57 | 0.04 | – | 2.01 |
trandolaprilat | – | – | – | 0.57 | 0.03 | – | 1.66 |
perfluorooctanoic acid | – | – | – | 0.56 | 1.31e-03 | – | 2.65 |
acylcarnitine 11:0 | – | – | – | 0.56 | 2.75e-06 | – | 2.57 |
acylcarnitine 13:0 | – | – | – | 0.56 | 3.36e-03 | – | 1.99 |
O2'-4a-cyclic-tetrahydrobiopterin | – | – | – | 0.55 | 2.90e-05 | – | 2.63 |
3,4,5-trimethoxycinnamic acid | – | – | – | 0.55 | 5.16e-03 | – | 2.22 |
catechol | – | – | – | 0.54 | 2.12e-03 | – | 2.57 |
pyrocatechol sulfate | – | – | – | 0.52 | 1.92e-03 | – | 2.80 |
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline | – | – | – | 0.50 | 1.36e-03 | – | 2.70 |
His-Thr | – | – | – | 0.49 | 1.57e-03 | – | 2.78 |
D8'-Merulinic acid A | – | – | – | 0.48 | 8.68e-03 | – | 1.99 |
2,4-dihydroxyacetophenone 5-sulfate | – | – | – | 0.40 | 5.56e-03 | – | 2.17 |
perfluorohexane sulfonic acid | – | – | – | 0.39 | 2.94e-04 | – | 2.87 |
Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
---|---|---|---|---|---|---|
12S-HHT | – | – | – | – | – | – |
LysoPC 14:0 | – | – | 0.895 | – | – | – |
beta-Santalyl acetate | – | – | – | – | – | – |
LysoPC 16:1 | – | – | – | – | – | – |
3-cyclohexyl-1,1-dimethylurea | – | – | – | – | – | – |
acetyl-DL-carnitine | – | – | – | – | – | – |
docosatrienoic acid | – | – | – | – | – | – |
Plasmenyl-PC 16:0; PC(P-14:0/2:0) | – | – | – | – | – | – |
LysoPE 18:3 | – | – | 0.908 | – | – | – |
8Z,14Z-Eicosadienoic acid | – | – | – | – | – | – |
5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid, 1,5-lactone | – | – | – | – | – | – |
LysoPE 18:2 | – | – | – | – | – | – |
desmethylofloxacin | – | – | – | – | – | – |
PC 9:0; PC(4:0/5:0) | – | – | – | – | – | – |
LysoPA 18:2; LysoPA 18:2 | – | – | – | – | – | – |
LysoPC 18:3 | – | – | 0.893 | – | – | – |
LysoPE 22:6 | – | – | – | – | – | – |
LysoPE 20:3 | – | – | – | – | – | – |
linoleoylcarnitine | – | – | – | – | – | – |
LysoPE 18:1 | – | – | – | – | – | – |
dehydrocarpaine I | – | – | – | – | – | – |
TG 62:17; TG(18:4/22:6/22:7) | – | – | – | – | – | – |
LysoPE 22:5 | – | – | – | – | – | – |
TG 66:21; TG(22:7/22:7/22:7) | – | – | – | – | – | – |
Plasmenyl-PE 18:0; PE(P-15:0/3:0) | – | – | – | – | – | – |
11.alpha.-Hydroxyprogesterone .beta.-D-glucuronide | – | – | – | – | – | – |
LysoPE 16:0 | – | – | – | – | – | – |
omega.-3 Arachidonic acid methyl ester | – | – | – | – | – | – |
acrolein | – | – | – | – | – | – |
Trp-Leu | – | – | – | – | – | – |
riboflavin | – | – | – | – | – | – |
5-hexyltetrahydro-2-furanoctanoic acid | – | – | – | – | – | – |
Neurine | – | – | – | – | – | – |
Trp-Glu | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
8-HETrE | – | – | – | – | – | – |
LysoPE 20:4 | – | – | – | – | – | – |
PC(16:0/20:3(5Z,8Z,11Z)) | – | – | – | – | – | – |
12R-Hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid | – | – | – | – | – | – |
ormosanine | – | – | – | – | – | – |
LysoPC 22:5 | – | – | – | – | – | – |
L-propionylcarnitine | – | – | – | – | – | – |
LysoPC 20:5 | – | – | – | – | – | – |
oleoyl-L-carnitine | – | – | – | – | – | – |
pyruvic acid | – | – | – | – | – | – |
7-hydroxyquetiapine | – | – | – | – | – | – |
LysoPC 22:6 | – | – | – | – | – | – |
N-lactoyl-leucine | – | – | – | – | – | – |
PC(18:3(6Z,9Z,12Z)/16:0) | – | – | – | – | – | – |
germbudine | – | – | – | – | – | – |
LysoPE 18:0 | – | – | – | – | – | – |
ent-16b,19-Kauranediol 19-acetate | – | – | – | – | – | – |
LysoPC 20:3 | – | – | – | – | – | – |
8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid | – | – | – | – | – | – |
Plasmenyl-PC 18:0; PC(P-14:0/4:0) | – | – | – | – | – | – |
palmitoylcarnitine | – | – | – | – | – | – |
(S)-Reticuline | – | – | – | – | – | – |
linoleic acid | – | – | – | – | – | – |
1,2-Di-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine | – | – | – | – | – | – |
adipoyl-L-carnitine | – | – | – | – | – | – |
acylcarnitine 18:3 | – | – | – | – | – | – |
methyl .gamma.-linolenate | – | – | – | – | – | – |
cocaine | – | – | – | – | – | – |
irbesartan | – | – | – | – | – | – |
11,14,17-eicosatrienoic acid, (Z,Z,Z)- | – | – | – | – | – | – |
LysoPC 17:1 | – | – | – | – | – | – |
1-(3-(Trifluoromethyl)phenyl)piperazine | – | – | – | – | – | – |
pyroglutamic acid | – | – | – | – | – | – |
drofenine | – | – | – | – | – | – |
glutamyltryptophan | – | – | – | – | – | – |
3-tert-Butyl-4-hydroxyanisole | – | – | – | – | – | – |
acylcarnitine 20:3 | – | – | – | – | – | – |
6-(3-Dimethylaminopropionyl)forskolin | – | – | – | – | – | – |
acylcarnitine 16:1 | – | – | – | – | – | – |
LysoPC 20:4 | – | – | – | – | – | – |
butaprost (free acid) | – | – | – | – | – | – |
4-methylumbelliferone | – | – | – | – | – | – |
LysoPC 18:0 | – | – | – | – | – | – |
LysoPS 20:4; LysoPS 20:4 | – | – | – | – | – | – |
stearamide | – | – | – | – | – | – |
LysoPC 16:0 | – | – | – | – | – | – |
acylcarnitine 20:2 | – | – | – | – | – | – |
chloridazone-methyl-desphenyl | – | – | – | – | – | – |
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | – | – | – | – | – | – |
2S-Amino-4E-octadecene-1,3S-diol | – | – | – | – | – | – |
9-oxoprosta-10,12Z,14E-trienoic acid | – | – | – | – | – | – |
2,2,6,7-Tetramethylbicyclo[4.3.0]nona-1(9),4-diene-7,8-diol | – | – | – | – | – | – |
methyl dihydrojasmonate | – | – | – | – | – | – |
perfluoroundecanoic acid | – | – | – | – | – | – |
drostanolone | – | – | – | – | – | – |
acylcarnitine 20:1 | – | – | – | – | – | – |
3-decen-2-one | – | – | – | – | – | – |
Plasmenyl-PC 44:5; PC(P-22:0/22:5) | – | – | – | – | – | – |
8-isoprostaglandin E2 | – | – | – | – | – | – |
hypoxanthine | – | – | 0.769 | – | – | – |
2-butyl-4-methylphenol | – | – | – | – | – | – |
AcylGlcADG 66:18; AcylGlcADG(22:6/22:6/22:6) | – | – | 0.906 | – | – | – |
isopropyl tiglate | – | – | – | – | – | – |
indoxyl sulfate | – | – | – | – | – | – |
paraxanthine | – | – | – | – | – | – |
decanoyl-L-Carnitine | – | – | – | – | – | – |
octanoylcarnitine | – | – | – | – | – | – |
theobromine | – | – | – | – | – | – |
inosine | – | – | – | – | – | – |
5.alpha.-Androstan-3.beta.-ol-17-one sulfate | – | – | – | – | – | – |
acylcarnitine 13:1 | – | – | – | – | – | – |
cyclamate | – | – | – | – | – | – |
1,2,3-Trihydroxybenzene | – | – | – | – | – | – |
trandolaprilat | – | – | – | – | – | – |
perfluorooctanoic acid | – | – | – | – | – | – |
acylcarnitine 11:0 | – | – | 0.854 | – | – | – |
acylcarnitine 13:0 | – | – | – | – | – | – |
O2'-4a-cyclic-tetrahydrobiopterin | – | – | – | – | – | – |
3,4,5-trimethoxycinnamic acid | – | – | – | – | – | – |
catechol | – | – | – | – | – | – |
pyrocatechol sulfate | – | – | – | – | – | – |
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline | – | – | – | – | – | – |
His-Thr | – | – | – | – | – | – |
D8'-Merulinic acid A | – | – | – | – | – | – |
2,4-dihydroxyacetophenone 5-sulfate | – | – | – | – | – | – |
perfluorohexane sulfonic acid | – | – | – | – | – | – |